Navigation Links
TGen drug development teams with Oncoholdings to fight cancer
Date:1/7/2011

SCOTTSDALE, Ariz. Jan. 7, 2010 TGen Drug Development (TD2) and Oncoholdings Inc. announced today a partnership agreement that could lead to the prompt development of new anti-cancer agents.

Oncoholdings Inc. is a Syracuse, N.Y.-based pharmaceutical company focused on acquiring and developing the most promising preclinical and early clinical anti-cancer agents. It was founded by some of the world's leading oncology scientists and leverages the unique insights and experiences of its founders and world-class scientific advisory board.

TD2, based in Scottsdale, Ariz., provides drug development firms with expertise in moving promising laboratory discoveries through the pre-clinical, clinical and regulatory approval steps of getting new drugs to patients as quickly and safely as possible.

Under the agreement announced today, TD2 a subsidiary of the Phoenix-based Translational Genomics Research Institute (TGen) will be the exclusive development partner for Oncoholdings' oncology portfolio. The company plans to develop as many as 15 early-stage drugs over the next three years.

"We are extremely eager to put the scientific assets of Oncoholdings on the most expeditious and precise path, moving their drug compounds safely and effectively to benefit cancer patients who so desperately need better treatments," said Dr. Stephen Gately, President of TD2 and a member of the Scientific Advisory Board of Oncoholdings.

Oncoholdings specifically targets drug candidates for development with the potential to:

  • Demonstrate superiority over standard-of-care in pre-clinical or early human trials.
  • Address significant unmet medical needs in oncology.
  • Leverage Oncoholdings' significant expertise in cancer trial design and execution.

"Through our partnership with TGen Drug Development we are confident that we have secured a team comprised of the of the world's top scientists and researchers to develop Oncoholdings' drug portfolio," said Dr. Jeffrey Evans, founder and Chief Executive Officer of Oncoholdings.

"TD2's vast knowledge and experience developing cancer therapies is important to Oncoholdings, as we are positioned to advance more than a dozen compounds with various mechanisms of action. We are very pleased to have found a partner that can meet the challenges of rapidly and effectively progressing our strategy," said Dr. Evans, who also is the former co-founder and President of Rondaxe, a leading pharmaceutical consultancy.

Oncoholdings expects to announce the acquisition of its first group of products in the first quarter of 2011. Among these first products is a novel first-in-class therapy, as well as products with clearly superior efficacy and safety profiles relative to existing therapeutics. Those interested in discussing opportunities with Oncoholdings are encouraged to contact Dr. Evans at: BusDev@oncoholdings.com


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinsons Drug Development
2. Hayes Announces Appointment Of Dr Susan Levine To The Medicare Evidence Development and Coverage Advisory Committee (MEDCAC)
3. Flat Head Syndrome Linked to Developmental Delays
4. Pharmacokinetic/Pharmacodynamic Data Support Further Development of Tobiras Next-Generation CCR5 Receptor Antagonist
5. Chemical tags likely to affect metabolism, cancer development
6. The role of sleep in brain development
7. Talaris Advisors Attracts Veteran Team of Strategic Drug Development Managers
8. Antidepressants in Pregnancy May Delay Developmental Milestones
9. Secretary Clintons Approach to Development: Good Rhetoric, Little Action?
10. Sisters of Charity Health System Welcomes Mark Wiedt to its Business Development Team
11. Avoiding Dairy Due to Lactose Intolerance is Unnecessary in Most Cases and May Pose Diet and Health Risks, Concludes National Institutes of Health Consensus Development Conference Panel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... the California Dental Association, today announced it has signed a letter of intent ... Corporation (DBC) and Northwest Dentists Insurance Company (NORDIC). , Started by dentists 36 ...
(Date:4/28/2016)... ... 28, 2016 , ... CastCoverz!, America’s #1 trusted brand for ... oldest waterproof cast protector . As the largest one-stop, orthopedic shop, CastCoverz! ... daily, night, weatherproof and waterproof covers for most orthopedic devices, including but not ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... the organization’s most successful events, attracting medical professionals from around the globe who ... networking events. , Opening Ceremonies Sunday, April 17 included the introduction of the ...
(Date:4/28/2016)... ... April 28, 2016 , ... In many parts of the world, ... childhood mortality. This is particularly true in underdeveloped parts of Africa where clean sources ... New England’s campus in Tangier, Morocco, will examine this global health issue and consider ...
(Date:4/28/2016)... ... 28, 2016 , ... Cognizin® Citicoline is one of three ... the Healthy Ageing category, Cognizin® is being considered for this prestigious honor due ... include everything from antioxidants, lipids, proteins, and botanicals. NutraIngredients will choose a winner ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ... on the development of oral drug delivery systems, announced today ... conference, presented by Joseph Gunnar & Co. LLC, ... York . Nadav Kidron , CEO of Oramed, ... Presentation Details:   PIONEERS 2016, presented by ...
(Date:4/28/2016)... , April 28, 2016  ValGenesis, Inc., ... Management Solutions (VLMS) today announced that a ... for sufferers of chronic kidney failure has ... manage their corporate validation process. The global ... software solution to manage their validation processes ...
(Date:4/28/2016)... , April 28, 2016 ... H1 2016" is a report that provides an ... strengthen R&D pipelines by identifying new targets and ... Company Profiles discussed in this H1 2016 ... Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx ...
Breaking Medicine Technology: